Alzheimer's Disease Expert Lab (adel), Inc.

This early-stage study tested a new drug called ADEL-Y01 in healthy volunteers and people with mild Alzheimer's or mild cognitive impairment. The goal was to check safety, side effects, and how the drug moves through the body. The trial was stopped early, so results are limited.